GE Healthcare Technologies Inc
NASDAQ:GEHC

Watchlist Manager
GE Healthcare Technologies Inc Logo
GE Healthcare Technologies Inc
NASDAQ:GEHC
Watchlist
Price: 82.44 USD 0.54% Market Closed
Market Cap: 37.7B USD
Have any thoughts about
GE Healthcare Technologies Inc?
Write Note
Section:
 
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

GEHC Price Targets Summary
GE Healthcare Technologies Inc

Wall Street analysts forecast GEHC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GEHC is 99.47 USD with a low forecast of 74.74 USD and a high forecast of 115.5 USD.

GEHC Lowest Forecast
Wall Street Target
74.74 USD
9% Downside
GEHC Average Forecast
Wall Street Target
99.47 USD
21% Upside
GEHC Highest Forecast
Wall Street Target
115.5 USD
40% Upside
Lowest
Price Target
74.74 USD
9% Downside
Average
Price Target
99.47 USD
21% Upside
Highest
Price Target
115.5 USD
40% Upside

GEHC Last Price Targets
GE Healthcare Technologies Inc

The latest public price target was made on Nov 15, 2024 by Jason Bednar from Piper Sandler , who expects GEHC stock to rise by 18% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Jason Bednar
Piper Sandler
97 USD
Upside 18%
1 week ago
Nov 15, 2024
Piper Sandler Reiterates Overweight Rating on GE HealthCare (GEHC)
StreetInsider
Graham Doyle
UBS
74 USD
Downside 10%
1 month ago
Sep 26, 2024
GE HealthCare downgraded to Sell from Neutral at UBS
TheFly
Craig Bijou
Bank of America Securities
97 USD
Upside 18%
2 months ago
Sep 20, 2024
GE HealthCare price target raised to $97 from $86 at BofA
TheFly
Ryan Zimmerman
BTIG
100 USD
Upside 21%
2 months ago
Sep 18, 2024
GE HealthCare upgraded to Buy from Neutral at BTIG
TheFly
David Roman
Goldman Sachs
87 USD
Upside 6%
5 months ago
May 30, 2024
GE HealthCare initiated with a Neutral at Goldman Sachs
TheFly
Jason Bednar
Piper Sandler
92 USD
Upside 12%
6 months ago
May 21, 2024
Piper Sandler Reiterates Overweight Rating on GE HealthCare (GEHC)
StreetInsider
Anthony Petrone
Mizuho Securities
105 USD
Upside 27%
6 months ago
May 1, 2024
GE HealthCare (GEHC) PT Lowered to $105 at Mizuho
StreetInsider
Vijay Kumar
Evercore ISI
96 USD
Upside 16%
6 months ago
Apr 30, 2024
GE HealthCare (GEHC) PT Lowered to $96 at Evercore ISI
StreetInsider
Anthony Petrone
Mizuho Securities
110 USD
Upside 33%
7 months ago
Apr 11, 2024
GE HealthCare (GEHC) PT Raised to $110 at Mizuho, Keeps name Top Large-cap Pick, 'see the set-up as net bullish'
StreetInsider
David Toung
Argus Research
110 USD
Upside 33%
7 months ago
Apr 1, 2024
GE HealthCare (GEHC) PT Raised to $110 at Argus
StreetInsider
Patrick Wood
Morgan Stanley
76 USD
Downside 8%
1 year ago
Jun 27, 2023
GE HealthCare's Solid Demand And Sensible Margin Targets: Morgan Stanley Sees Potential Upside Despite Street's High Expectations
Benzinga
Suraj Kalia
Oppenheimer
97 USD
Upside 18%
1 year ago
May 16, 2023
GE HealthCare Technologies Is Innovating An $84B Market And This Analyst Is Bullish
Benzinga
Show More Price Targets
Show Less Price Targets
Jason Bednar
Piper Sandler
Price Target 97 USD
Upside/Downside 18%
View Source
Graham Doyle
UBS
Price Target 74 USD
Upside/Downside 10%
View Source
Craig Bijou
Bank of America Securities
Price Target 97 USD
Upside/Downside 18%
View Source
Ryan Zimmerman
BTIG
Price Target 100 USD
Upside/Downside 21%
View Source
David Roman
Goldman Sachs
Price Target 87 USD
Upside/Downside 6%
View Source
Jason Bednar
Piper Sandler
Price Target 92 USD
Upside/Downside 12%
View Source
Anthony Petrone
Mizuho Securities
Price Target 105 USD
Upside/Downside 27%
View Source
Vijay Kumar
Evercore ISI
Price Target 96 USD
Upside/Downside 16%
View Source
Anthony Petrone
Mizuho Securities
Price Target 110 USD
Upside/Downside 33%
View Source
David Toung
Argus Research
Price Target 110 USD
Upside/Downside 33%
View Source
Patrick Wood
Morgan Stanley
Price Target 76 USD
Upside/Downside 8%
View Source
Suraj Kalia
Oppenheimer
Price Target 97 USD
Upside/Downside 18%
View Source
Show More Price Targets
Show Less Price Targets
GE Healthcare Technologies Inc Competitors:
Price Targets
6823
Rion Co Ltd
43% Upside
DXR
Daxor Corp
157% Upside
AXGN
AxoGen Inc
34% Upside
J
287410
Jeisys Medical Inc
10% Upside
6823
Rion Co Ltd
43% Upside
DXR
Daxor Corp
157% Upside
AXGN
AxoGen Inc
34% Upside
J
287410
Jeisys Medical Inc
10% Upside
IRMD
IRadimed Corp
15% Upside
6869
Sysmex Corp
3% Upside
Z
ZOM
Zomedica Corp
96% Upside
J
002223
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
35% Upside

Revenue
Forecast

Revenue Estimate
GE Healthcare Technologies Inc

For the last 3 years the compound annual growth rate for GE Healthcare Technologies Inc's revenue is 4%. The projected CAGR for the next 3 years is 4%.

4%
Past Growth
4%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
GE Healthcare Technologies Inc

For the last 3 years the compound annual growth rate for GE Healthcare Technologies Inc's operating income is -4%. The projected CAGR for the next 3 years is 16%.

-4%
Past Growth
16%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
GE Healthcare Technologies Inc

For the last 3 years the compound annual growth rate for GE Healthcare Technologies Inc's net income is -54%. The projected CAGR for the next 3 years is 21%.

-54%
Past Growth
21%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
GEHC intrinsic value, competitors valuation, and company profile.
DCF Valuation
GEHC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GEHC stock valuation using valuation multiples.
Wall Street Estimates
GEHC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GEHC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GEHC's stock price target?
Price Target
99.47 USD

According to Wall Street analysts, the average 1-year price target for GEHC is 99.47 USD with a low forecast of 74.74 USD and a high forecast of 115.5 USD.

What is GE Healthcare Technologies Inc's Revenue forecast?
Projected CAGR
4%

For the last 3 years the compound annual growth rate for GE Healthcare Technologies Inc's revenue is 4%. The projected CAGR for the next 3 years is 4%.

What is GE Healthcare Technologies Inc's Operating Income forecast?
Projected CAGR
16%

For the last 3 years the compound annual growth rate for GE Healthcare Technologies Inc's operating income is -4%. The projected CAGR for the next 3 years is 16%.

What is GE Healthcare Technologies Inc's Net Income forecast?
Projected CAGR
21%

For the last 3 years the compound annual growth rate for GE Healthcare Technologies Inc's net income is -54%. The projected CAGR for the next 3 years is 21%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 201,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.